Atorvastatin/amlodipine
The drug combination atorvastatin/amlodipine (trade names Caduet in the US, Australia and Russia, and Envacar elsewhere) is a medication approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol and high blood pressure. It is a fixed-dose combination drug containing a HMG-CoA reductase inhibitor and a calcium channel blocker being marketed by the pharmaceutical company Pfizer.[1][2]
Combination of | |
---|---|
Amlodipine | Calcium channel blocker |
Atorvastatin | Statin |
Clinical data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
PubChem CID | |
ChemSpider | |
(verify) |
References
- "CADUET (amlodipine besylate/atorvastatin calcium) Tablets" (PDF). NDA 21-540/S-009. United States Food and Drug Administration. February 2010. Retrieved 2010-09-25.
- Devabhaktuni, Madhuri; Bangalore, Sripal (2009). "Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives". Vascular Health and Risk Management. 5 (1): 377–387. doi:10.2147/vhrm.s3339. ISSN 1178-2048. PMC 2686256. PMID 19475775.
External links
- Manufacturer's site (caduet.com)
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.